Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell massBart Keymeulen, Daniël Pipeleers, Frans Gorus et al.|Diabetologia|2010Cited by 313
Identification and characterisation of the dose response of otelixizumab in new onset type 1 diabetes patientsAntonio Napolitano, Bart Keymeulen, André van Maurik et al.|VUBIR (Vrije Universiteit Brussel)|2019Cited by 0